Precontrast and postcontrast susceptibility-weighted imaging in the assessment of intracranial brain neoplasms at 1.5 T

Japanese Journal of Radiology

Volumn 28, Issue 4, 2010, Pages 299-304

  Hori, Masaaki ^a,d   Ishigame, Keiichi ^a   Kabasawa, Hiroyuki ^b   Kumagai, Hiroshi ^a   Ikenaga, Satoshi ^a   Shiraga, Nobuyuki ^c   Aoki, Shigeki ^d   Araki, Tsutomu ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

Brain neoplasm; Contrast enhancement; MRI; Susceptibility weighted imaging

Indexed keywords

GADOLINIUM;

ADULT; ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; GLIOBLASTOMA; HUMAN; INTRACRANIAL TUMOR; MALE; MENINGIOMA; METASTASIS; NEURILEMOMA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; STUDENT T TEST; WILCOXON SIGNED RANKS TEST;

BRAIN NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 77955485417     PISSN: 18671071     EISSN: 1867108X     Source Type: Journal    
DOI: 10.1007/s11604-010-0427-z     Document Type: Article

References (9)

1. Haacke EM, Xu Y, Cheng YC, Reichenbach JR. Susceptibility weighted imaging (SWI). Magn Reson Med 2004;52:612-8. (Pubitemid 39108975)
2. Rauscher A, Sedlacik J, Barth M, Haacke EM, Reichenbach JR. Noninvasive assessment of vascular architecture and function during modulated blood oxygenation using susceptibility weighted magnetic resonance imaging. Magn Reson Med 2005;54:87-95. (Pubitemid 40898400)
3. A. Rauscher, J. Sedlacik, M. Barth, H.J. Mentzel, J.R. Reichenbach 2005 Magnetic susceptibility-weighted MR phase imaging of the human brain AJNR Am J Neuroradiol 26 736 742 (Pubitemid 43079761)
4. Sehgal V, Delproposto Z, Haacke EM, Tong KA, Wycliffe N, Kido DK, et al. Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 2005; 22:439-50. (Pubitemid 41416402)
5. Sehgal V, Delproposto Z, Haacke EM, Tong KA, Wycliffe N, Kido DK, et al. Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 2005; 22:439-50.
6. K. Pinker I.M. Noebauer-Huhmann I. Stavrou R. Hoeftberger P. Szomolanyi G. Karanikas, et al. 2007 High-resolution contrastenhanced, susceptibility- weighted MR imaging at 3T in patients with brain tumors: correlation with positron-emission tomography and histopathologic fi ndings. AJNR Am J Neuroradiol 2007;2:1280-6. (Pubitemid 47309659)
7. Pinker K, Noebauer-Huhmann IM, Stavrou I, Hoeftberger R, Szomolanyi P, Karanikas G, et al. High-fi eld, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher fi eld strength in patients with brain tumors. Neuroradiology 2008;50:9-16.
8. Park MJ, Kim HS, Jahng GH, Ryu CW, Park SM, Kim SY. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-fi eld high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol 2009;30:1402-8.
9. Lin W, Mukherjee P, An H, Yu Y, Wang Y, Vo K, et al. Improving high-resolution MR bold venographic imaging using a T1 reducing contrast agent. J Magn Reson Imaging 1999;10:118-23. (Pubitemid 29362424)